Pharmaceutical Executive
In case anyone missed the recent wave of studies and reports documenting rising expenditures on medicines, Families USA weighed in with an analysis that further documents rising prices of medicines prescribed for the elderly. The report surfaced just before the US House of Representatives voted on a Medicare pharmacy benefit and was timed to influence that debate.
In case anyone missed the recent wave of studies and reports documenting rising expenditures on medicines, Families USA weighed in with an analysis that further documents rising prices of medicines prescribed for the elderly. The report surfaced just before the US House of Representatives voted on a Medicare pharmacy benefit and was timed to influence that debate. (See " Washington Report,")
In analyzing cost increases for the 50 medicines most used by seniors, the report found that prices for many of those products rose much faster than inflation and that the cost increases of brand-name therapies outpaced generics. That creates huge problems for the many seniors living on fixed incomes, observed Families USA executive director Ron Pollack, who urged consumers to write members of Congress about the importance of adding a prescription drug benefit to Medicare. Manufacturers countered that retail pharmacy prices vary widely and provide a faulty measure of medicines' true costs. They also urged consumers to shop around.
Researchers at the Centers for Disease Control and Prevention (CDC) link spending hikes to a noticeable increase in physician prescribing. An analysis of patient data collected by the CDC's National Center for Health Statistics between 1985 and 1999 found a 34 percent jump in physicians' prescribing rates. Another finding is a big jump in the number of physicians who prescribe multiple medicines per patient visit. If those trends continue, spending on pharmaceuticals will double in the next five years, according to the report, published in the July/August 2002 issue of Health Affairs.
Study author Catharine Burt ascribes the boost in prescribing primarily to increases in patient age and the number of medical conditions per patient. Other factors include expanded pharmacy coverage, rising biomedical R&D, faster FDA approvals, and increased pharma marketing to physicians and consumers. Most of the prescribing increase occurred in a few drug classes: antidepressants, hyperlipidemia drugs, ACE inhibitors, antihistamines, and calcium channel blockers. (See chart.) The only drop was in antimicrobial agents. Psychiatrists recorded the largest rise in "drug mention" rates (during patient visits), while surgeons, cardiologists, and dermatologists' drug mentions declined.
Top-detailed theraputic classes accounted for...
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.